ASX - By Stock
|
KZA |
Re:
Ann: Paxalisib receives Fast Track Designation from US FDA
|
|
Pbnewby
|
42 |
12K |
9 |
12/07/23 |
12/07/23 |
ASX - By Stock
|
42
|
12K
|
9
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Executive Leadership changes - Dr John Friend appointed CEO
|
|
Pbnewby
|
55 |
17K |
3 |
04/05/23 |
04/05/23 |
ASX - By Stock
|
55
|
17K
|
3
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia result of Share Purchase Plan
|
|
Pbnewby
|
14 |
5.1K |
8 |
28/02/23 |
28/02/23 |
ASX - By Stock
|
14
|
5.1K
|
8
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia raises $4.5m and launches share purchase plan
|
|
Pbnewby
|
32 |
11K |
4 |
17/01/23 |
17/01/23 |
ASX - By Stock
|
32
|
11K
|
4
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia receives Nasdaq minimum bid notice
|
|
Pbnewby
|
6 |
2.1K |
2 |
13/12/22 |
13/12/22 |
ASX - By Stock
|
6
|
2.1K
|
2
|
|
ASX - By Stock
|
KZA |
Re:
Ann: EVT801 preclinical data published
|
|
Pbnewby
|
47 |
12K |
6 |
08/12/22 |
08/12/22 |
ASX - By Stock
|
47
|
12K
|
6
|
|
ASX - By Stock
|
KZA |
Re:
Ann: EVT801 preclinical data published
|
|
Pbnewby
|
47 |
12K |
6 |
05/12/22 |
05/12/22 |
ASX - By Stock
|
47
|
12K
|
6
|
|
ASX - By Stock
|
KZA |
Re:
Ann: EVT801 preclinical data published
|
|
Pbnewby
|
47 |
12K |
3 |
05/12/22 |
05/12/22 |
ASX - By Stock
|
47
|
12K
|
3
|
|
ASX - By Stock
|
KZA |
Re:
Ann: EVT801 preclinical data published
|
|
Pbnewby
|
47 |
12K |
1 |
02/12/22 |
02/12/22 |
ASX - By Stock
|
47
|
12K
|
1
|
|
ASX - By Stock
|
KZA |
Re:
Ann: EVT801 preclinical data published
|
|
Pbnewby
|
47 |
12K |
2 |
02/12/22 |
02/12/22 |
ASX - By Stock
|
47
|
12K
|
2
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Application for quotation of securities - KZA
|
|
Pbnewby
|
17 |
7.2K |
4 |
20/09/22 |
20/09/22 |
ASX - By Stock
|
17
|
7.2K
|
4
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Application for quotation of securities - KZA
|
|
Pbnewby
|
17 |
7.2K |
2 |
19/09/22 |
19/09/22 |
ASX - By Stock
|
17
|
7.2K
|
2
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Application for quotation of securities - KZA
|
|
Pbnewby
|
17 |
7.2K |
1 |
17/09/22 |
17/09/22 |
ASX - By Stock
|
17
|
7.2K
|
1
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Application for quotation of securities - KZA
|
|
Pbnewby
|
17 |
7.2K |
3 |
16/09/22 |
16/09/22 |
ASX - By Stock
|
17
|
7.2K
|
3
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Application for quotation of securities - KZA
|
|
Pbnewby
|
7 |
2.3K |
7 |
15/08/22 |
15/08/22 |
ASX - By Stock
|
7
|
2.3K
|
7
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Application for quotation of securities - KZA
|
|
Pbnewby
|
7 |
2.3K |
4 |
15/08/22 |
15/08/22 |
ASX - By Stock
|
7
|
2.3K
|
4
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Interim data from MSKCC study
|
|
Pbnewby
|
47 |
21K |
5 |
08/08/22 |
08/08/22 |
ASX - By Stock
|
47
|
21K
|
5
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Interim data from MSKCC study
|
|
Pbnewby
|
47 |
21K |
17 |
08/08/22 |
08/08/22 |
ASX - By Stock
|
47
|
21K
|
17
|
|
ASX - By Stock
|
KZA |
Re:
Ann: GBM Agile Update
|
|
Pbnewby
|
178 |
63K |
3 |
05/08/22 |
05/08/22 |
ASX - By Stock
|
178
|
63K
|
3
|
|
ASX - By Stock
|
KZA |
Re:
Ann: GBM Agile Update
|
|
Pbnewby
|
178 |
63K |
3 |
05/08/22 |
05/08/22 |
ASX - By Stock
|
178
|
63K
|
3
|
|
ASX - By Stock
|
KZA |
Re:
Ann: GBM Agile Update
|
|
Pbnewby
|
178 |
63K |
7 |
04/08/22 |
04/08/22 |
ASX - By Stock
|
178
|
63K
|
7
|
|
ASX - By Stock
|
KZA |
Re:
Ann: GBM Agile Update
|
|
Pbnewby
|
178 |
63K |
5 |
03/08/22 |
03/08/22 |
ASX - By Stock
|
178
|
63K
|
5
|
|
ASX - By Stock
|
KZA |
Re:
Ann: GBM Agile Update
|
|
Pbnewby
|
178 |
63K |
6 |
03/08/22 |
03/08/22 |
ASX - By Stock
|
178
|
63K
|
6
|
|
ASX - By Stock
|
KZA |
Re:
Ann: GBM Agile Update
|
|
Pbnewby
|
178 |
63K |
6 |
02/08/22 |
02/08/22 |
ASX - By Stock
|
178
|
63K
|
6
|
|
ASX - By Stock
|
KZA |
Re:
Ann: GBM Agile Update
|
|
Pbnewby
|
178 |
63K |
9 |
02/08/22 |
02/08/22 |
ASX - By Stock
|
178
|
63K
|
9
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia licenses paxalisib to Simcere in Greater China
|
|
Pbnewby
|
112 |
33K |
1 |
02/08/22 |
02/08/22 |
ASX - By Stock
|
112
|
33K
|
1
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia licenses paxalisib to Simcere in Greater China
|
|
Pbnewby
|
112 |
33K |
3 |
02/08/22 |
02/08/22 |
ASX - By Stock
|
112
|
33K
|
3
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia licenses paxalisib to Simcere in Greater China
|
|
Pbnewby
|
112 |
33K |
0 |
02/08/22 |
02/08/22 |
ASX - By Stock
|
112
|
33K
|
0
|
|
ASX - By Stock
|
KZA |
Re:
Ann: GBM Agile Update
|
|
Pbnewby
|
178 |
63K |
8 |
02/08/22 |
02/08/22 |
ASX - By Stock
|
178
|
63K
|
8
|
|
ASX - By Stock
|
KZA |
Re:
Its a dead duck
|
|
Pbnewby
|
69 |
24K |
1 |
01/08/22 |
01/08/22 |
ASX - By Stock
|
69
|
24K
|
1
|
|
ASX - By Stock
|
KZA |
Re:
Ann: GBM Agile Update
|
|
Pbnewby
|
178 |
63K |
2 |
01/08/22 |
01/08/22 |
ASX - By Stock
|
178
|
63K
|
2
|
|
ASX - By Stock
|
KZA |
Re:
Ann: GBM Agile Update
|
|
Pbnewby
|
178 |
63K |
3 |
01/08/22 |
01/08/22 |
ASX - By Stock
|
178
|
63K
|
3
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Pbnewby
|
15 |
4.1K |
6 |
29/07/22 |
29/07/22 |
ASX - By Stock
|
15
|
4.1K
|
6
|
|
ASX - By Stock
|
KZA |
Re:
Simcere Therapeutics
|
|
Pbnewby
|
2 |
1.0K |
12 |
20/07/22 |
20/07/22 |
ASX - By Stock
|
2
|
1.0K
|
12
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia launches new SAB
|
|
Pbnewby
|
56 |
15K |
7 |
19/07/22 |
19/07/22 |
ASX - By Stock
|
56
|
15K
|
7
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia launches new SAB
|
|
Pbnewby
|
56 |
15K |
3 |
19/07/22 |
19/07/22 |
ASX - By Stock
|
56
|
15K
|
3
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia launches new SAB
|
|
Pbnewby
|
56 |
15K |
11 |
19/07/22 |
19/07/22 |
ASX - By Stock
|
56
|
15K
|
11
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Application for quotation of securities - KZA
|
|
Pbnewby
|
22 |
6.4K |
4 |
11/07/22 |
11/07/22 |
ASX - By Stock
|
22
|
6.4K
|
4
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia progress update
|
|
Pbnewby
|
38 |
11K |
4 |
30/06/22 |
30/06/22 |
ASX - By Stock
|
38
|
11K
|
4
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia progress update
|
|
Pbnewby
|
38 |
11K |
3 |
30/06/22 |
30/06/22 |
ASX - By Stock
|
38
|
11K
|
3
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Change in substantial holding
|
|
Pbnewby
|
55 |
12K |
2 |
27/06/22 |
27/06/22 |
ASX - By Stock
|
55
|
12K
|
2
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Change in substantial holding
|
|
Pbnewby
|
55 |
12K |
9 |
27/06/22 |
27/06/22 |
ASX - By Stock
|
55
|
12K
|
9
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia's paxalisib gains ODD for ATRT
|
|
Pbnewby
|
9 |
3.1K |
2 |
17/06/22 |
17/06/22 |
ASX - By Stock
|
9
|
3.1K
|
2
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia's paxalisib gains ODD for ATRT
|
|
Pbnewby
|
9 |
3.1K |
3 |
17/06/22 |
17/06/22 |
ASX - By Stock
|
9
|
3.1K
|
3
|
|
ASX - By Stock
|
KZA |
Re:
Ann: FDA AWARDS ORPHAN DESIGNATION TO PAXALISIB FOR ATRT
|
|
Pbnewby
|
5 |
2.1K |
13 |
17/06/22 |
17/06/22 |
ASX - By Stock
|
5
|
2.1K
|
13
|
|
ASX - By Stock
|
KZA |
Re:
Ann: FDA AWARDS ORPHAN DESIGNATION TO PAXALISIB FOR ATRT
|
|
Pbnewby
|
5 |
2.1K |
1 |
17/06/22 |
17/06/22 |
ASX - By Stock
|
5
|
2.1K
|
1
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia paxalisib preclinical DIPG data released at IPSNO
|
|
Pbnewby
|
12 |
5.1K |
12 |
15/06/22 |
15/06/22 |
ASX - By Stock
|
12
|
5.1K
|
12
|
|
ASX - By Stock
|
KZA |
Re:
KZA Media Thread
|
|
Pbnewby
|
2.0K |
618K |
10 |
09/06/22 |
09/06/22 |
ASX - By Stock
|
2.0K
|
618K
|
10
|
|
ASX - By Stock
|
KZA |
Re:
News: KZA Kazia Says Phase II Study Of Paxalisib In Brain Metastases Advances To Expansion Stage In...
|
|
Pbnewby
|
17 |
5.2K |
7 |
08/06/22 |
08/06/22 |
ASX - By Stock
|
17
|
5.2K
|
7
|
|
ASX - By Stock
|
KZA |
Re:
News: KZA Kazia Says Phase II Study Of Paxalisib In Brain Metastases Advances To Expansion Stage In...
|
|
Pbnewby
|
17 |
5.2K |
8 |
08/06/22 |
08/06/22 |
ASX - By Stock
|
17
|
5.2K
|
8
|
|